We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis AG said the European Medicines Agency committee is recommending against European approval of Zelnorm, its treatment for women with irritable bowel syndrome.
In a move that has been widely regarded as a setback for the multinational sector, an Israeli parliamentary committee has approved a measure easing development of generics during patent terms on original drugs.
According to local press reports, Brazil's antitrust regulator CADE will file a case against four drug companies for alleged price manipulation prior to 2000.
LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE) ("LAB"), an integrated drug development company with subsidiaries focused on developing therapies for the inhalation market and on providing contract research services, today announced that it has raised $12.3 million through the non-brokered private placement of 13 996 466 common shares at a price of $0.88 per share.
American Oriental Bioengineering Inc. (AMEX: AOB), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that on Thursday, Dec. 1, 2005, options on the company's common stock began trading on the Chicago Board Options Exchange ("CBOE").
Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today its European subsidiary, Samaritan Europe has entered into an exclusive distribution agreement with Three Rivers Pharmaceuticals for the marketing and sales of Amphocil(R) (amphotericin B cholesteryl sulfate complex for injection) in Greece and Cyprus.
Maxygen Inc. said Wednesday that it received a $5 million milestone from Swiss drug maker Roche Holding Ltd. in their collaboration to develop hepatitis treatments.